How to appeal a Humana cardiology drugs denial
42 CFR Part 422 Subpart M (Medicare Advantage) · 60-day window · 30-day decision
To appeal a Humana cardiology drugs denial, file an internal appeal within 60 days of the date on the denial letter through Humana's member or provider portal, under 42 CFR Part 422 Subpart M (Medicare Advantage). Humana returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).
Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.
What Humana's policy requires for cardiology drugs
Cited policy: Humana Pharmacy Coverage Policy: Tafamidis (Vyndaqel/Vyndamax)
Confirmed ATTR-CM per Maurer algorithm. NYHA I-III. Life expectancy >6 months. Cardiologist Rx.
How Humana denies cardiology drugs — and how to counter it
Where Humana pushes back: 1) Medicare Part D step therapy ('stable on alternative'); 2) Quantity limit on Vyndaqel 80mg; 3) Life expectancy attestation missing.
Counter-arguments that hold up: Provide cardiologist NYHA + life-expectancy attestation. Cite Vyndamax 61mg single capsule (FDA-approved 2019) as bioequivalent to Vyndaqel 80mg (4×20mg) — formulation choice rationale. 2024 CMS MA rule — must follow Medicare baseline. ATTR-ACT NEJM 2018.
What Humana typically denies for cardiology drugs
Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For cardiology drugs, expect:
- MA plan step therapy on Part B drugs
- Skilled nursing facility days
- Prior auth on specialty drugs
- OON emergency reduction
Treatments most often denied in this category
These are the cardiology drugs treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Repatha
- Praluent
- Leqvio
- Entresto
- SGLT2i for HF
- Verquvo
How to submit the appeal to Humana
- Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
- File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal a Humana cardiology drugs denial?
Humana allows 60 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit a Humana appeal?
Members can submit through the Humana member portal at https://www.humana.com. Providers should use the provider portal at https://www.humana.com/provider. Faxed and mailed appeals are accepted but take longer.
What denials does Humana most often issue for cardiology drugs?
For cardiology drugs, Humana most often denies on: 1) Medicare Part D step therapy ('stable on alternative'); 2) Quantity limit on Vyndaqel 80mg; 3) Life expectancy attestation missing. The strongest counters: Provide cardiologist NYHA + life-expectancy attestation. Cite Vyndamax 61mg single capsule (FDA-approved 2019) as bioequivalent to Vyndaqel 80mg (4×20mg) — formulation choice rationale. 2024 CMS MA rule — must follow Medicare baseline. ATTR-ACT NEJM 2018.
What if Humana denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Cardiology drugs appeal
Upload your Humana denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to 42 CFR Part 422 Subpart M (Medicare Advantage).
Get started →Contact: hello@denialhelp.com